View 2 reports from 1 analysts offering long term price targets
for J B Chemicals & Pharmaceuticals Ltd..
J B Chemicals & Pharmaceuticals Ltd. has an average target of 1963.00. The consensus estimate
represents an upside of 22.70%
from the last price of 1599.90.
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
JB Chemicals & Pharmaceuticals’ (JBCPL) Q3FY22 performance was better than our estimates on operational fronts. Excluding revenue deferred to Q3FY21 from Q2FY21, consolidated revenue grew 23% YoY to Rs6bn (I-Sec est: 5.8bn). EBITDA margin stood at 21.3%, higher than our estimate of 19.8%.
JB Chemicals & Pharmaceuticals’ (JBCPL) Q2FY22 performance was better than estimates driven by strong growth in India business. EBITDA margin was lower than estimates owing to ESOPs charge. Consolidated revenue grew 33.7% YoY to Rs5.9bn and EBITDA margin dropped 340bps to 21.4%.
J.B. Chemicals & Pharmaceuticals Ltd (JBCP) is one of the fastest growing company in the IPM on the back of its brand and therapy focused strategy. Its strong domestic franchisee (>85% sales from 5 mega brands: Cilacar & Nicardia in Cardiac and Metrogyl & Rantac in Gastro-Intestinal) enjoy enormous brand equity which allows them to earn >35% EBITDA margins. While unwinding of erst-while promoter's transactions provide a permanent shift in base, EBITDA margins likely to be supported at the current levels on account to productivity improvements and renewed focus on CMO, US generics and Russia business. We valued JBCP using SOTP based methodology; valuing Domestic franchisee at 7x FY23E EV/Sales and Exports business at 4x FY23E EV/Sales given their inherent quality. We thus initiate coverage on JBCP with BUY rating and target price of INR 2,000 which is ~33% upside on CMP. At our target price, JBCP is available at 26x FY23E PER; on the CMP JBCP trades at 20x FY23E PER....
Company has been ranked 28th in the IPM, has increased its position by 4 ranks in the last 12 months JB Domestic branded generic growth has outpaced the market by ~500bp/yr...
JBCP conducted its first analyst meet post KKR acquired 54% stake in CY20. Guided for higher share of revenue from chronic portfolio in India formulation to 60% (vs. 48% in 9MFY21) in FY23E led by 1) new launches and foray in new therapy, 2) Rx share gain in existing brands 3) MR productivity improvement by 12-14% from current Rs4.5lakhs/month and 4) 50% CAPEX allocation towards Indian market. JBCP also guided for an increase in its US filing rate to 5-6 ANDAs per year (from 1-2 ANDAs) along with launches of new brands in Russian market, however India formulations to remain key growth pillar....
JBCPL reported a strong Q1, led by 8.6% YoY growth in domestic formulations (11% QoQ despite a high base) vs IPM de-growth of 5%. The sharp growth was driven by cardiac portfolio (up 24%) Cilacar and Nicardia as acute declined 1% YoY. Exports (both formulations and API) grew 28% YoY led by higher stocking. Improved product mix coupled with lower opex led EBITDA margins surge to 34% (up 980 bps YoY). Management expects to outperform IPM growth and sustenance in export growth in FY21E. Further, it remains confident of its growth in the...
While we don't actively cover JBCP, a fair value of Rs 470/sh (at 14x FY21E EPS, 5-year avg P/E) is apparent to us. We recently met the management of J B Chemicals & Pharmaceuticals (JBCP), an Indian pharma company with legacy brands like Rantac and Metrogyl. It is also present in markets like Russia and South Africa. Cos track-record has been mostly steady with ~10/15/18% rev/EBITDA/PAT CAGR over FY15-19E, driven by 15% growth in the India segment (~45% of revenues in FY19E).
J.B. Chemicals & Pharmaceuticals Ltd (JBCPL) is India's leading pharmaceutical company that manufactures & markets a range of pharmaceutical formulations, herbal remedies and APIs. It exports to many countries globally. Field force expansion along with new product launches given company's continued...
J. B. Chemicals & Pharmaceuticals Limited (JBCPL) is a pharmaceutical company. The Company manufactures and markets a range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredient (APIs). The Company's business segments include domestic formulation business, exports and API business. The Company markets various contrast media products in India, such as Contrapaque (Iohexol), Lek Pamidol (Iopamidol), Trazograf (Diatrazoic acid), Trazogastro - Oral contrast (Diatrazoic acid), Magnilek Injection (Gadopentatic acid) and Cardiolek Injection (Iodixanol). The Company's brands for the Indian pharmaceutical market...
JBCPL, one of India's leading pharmaceutical companies, manufactures and markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong...
JBCPL, one of India's leading pharmaceutical companies, manufactures and markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in in Russia, Ukraine, CIS countries and South Africa.
The income from operations in FY16, which was the highest in a decade, registered a growth of a 9.7% y-o-y. The company which has seen better profit margins in the past (read: FY10 and FY11), exhibited an operating profit margin of 16.4% and a net profit margin of 12.2 During the year, Biotech Laboratories (Pty.) Ltd., South Afri subsidiary of the company, with company’s interest going up to 95.24% from 49%. This strategic investment will allow the Company to expand its business in South Africa and SADC countries, which hold good growth potential.The domestic formulation business which somehow managed to contribute 35% in the Q4FY16, grew almost 31% q-o-q, contributing a beefy 43% last quarter i.e., Q1FY17. The volatile currency situation cast down the exports, which rendered a decline of 11.2% q-o-q.
JBCPL, one of India's leading pharmaceutical companies, which is engaged in manufacturing & marketing of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to more than 30...
Other income boosts profits, exports to rev up long term growth JB Chemicals (JBCPL)'s 2Q result beat our estimate on the profitability front boosted by higher other income (sale of investment). Sales were muted on the back of weak export formulations (impacted by currency headwinds in ROW markets). India formulations (12% yoy) and Russia (up 35% yoy) performed in line. Reported margins at 17.3% (down 180bps yoy, up 90bps qoq) were in-line with our assumption of margin recovery from 2Q onwards led by tender sales. We draw comfort from company's steady performance and healthy free cash generation and...
Compare Stocks
